Airtificial diversifies and expands into the pharmaceuticals sector
- Airtificial moves forward with its diversification strategy of markets and customers with the entry into the pharmaceutical sector due to the strong demand for industrial projects of production optimisation.
- The Company has reached a first agreement that allows it to launch the new division, Airtificial Health Smart Tech, which will address the demands of a sector facing a myriad of challenges following the significant increase in life expectancy, the growing demand for digital health technologies or the situation of drug shortages due to tensions in the supply chain.
- The new business unit will employ the proprietary AI-driven optimisation technology platform, AiTRACE®, as well as other advanced technologies, including machine vision and digital twins, which enable intelligent optimisation of the production chain, as well as process automation that significantly improves efficiency and ensures biosafety.
- The entry into the pharmaceutical sector represents a further step in the Airtificial Group’s scalability and its flexible business capacity, capable of providing great technological value to various highly demanding industrial sectors.
Airtificial, the leading technology group in the optimisation of process engineering, has achieved a new milestone in its strategy of diversification and market expansion with its entry into the pharmaceutical sector. The Company thus launches its new business unit specialised in the operational improvement of manufacturing in the healthcare industry, Airtificial Health Smart Tech, where it applies its more than 25 years of experience in various industrial sectors with cutting-edge technologies such as collaborative, industrial and mobile robotics; algorithms based on Artificial Intelligence and artificial vision; and augmented and virtual reality. Airtificial’s arrival in the healthcare sector coincides with the signing of a first agreement for the optimisation of a production chain.
The industrial production of medicines, pharmaceuticals and other healthcare products requires a high degree of automation to cope with the growing global demand for healthcare products and services. This increase in demand responds to the current and future challenges of the sector, derived from the continuous increase in life expectancy, the rise in chronic diseases and the exponential increase in the world’s population, among others. All of this, in a context such as the current one, in which the sector has to face a situation of major shortages of medicines due to tensions in the supply chain.
Airtificial has now reached the pharmaceutical industry with the mission to revolutionise its industrial production capabilities by applying its own knowledge, technology and expertise. These intangibles are nourished by more than 25 years of experience in the optimisation of various industrial processes in the automotive industry, in which it has successfully delivered more than a thousand projects of high industrial value around the world.
With the in-house AiTRACE® traceability technology platform at its core, Airtificial uses Artificial Intelligence to significantly reduce manufacturing times and product launches more efficiently, accurately and cost-effectively through automated industrialisation of production lines or optimisation of entire smart production plants. Airtificial also integrates advanced technologies such as robotics, machine vision in both production and laboratory equipment, digital twins that enable intelligent production optimisation, and automation that prevents errors before they occur, while improving biosafety and increasing accuracy.
The new agreement that Airtificial has reached in this area involves the implementation of AiTRACE® technology, which includes real-time production performance indicators and anticipation of possible errors or inefficiencies in production processes. The platform uses algorithms based on Artificial Intelligence to be able to capture the big data of a production process, manage it and interpret it to ensure maximum performance, in pursuit of effectiveness and efficiency.
Guillermo Fernández de Peñaranda, CEO of Airtificial, states: “Our entry into the pharmaceutical industry is a major milestone for Airtificial, as well as representing a further step in the Group’s diversification strategy. Airtificial has the capabilities that make the difference in a demanding industry such as Heath, especially through our deep know-how and our capacity for constant innovation with technologies such as Artificial Intelligence, which we have developed and applied in high-performance industrial sectors where it has been present for decades. These are intangible capabilities that are, practically, transversal to any industry and above all thanks to our own technological developments, such as our AiTRACE® platform”.
About Airtificial
Airtificial provides global and innovative design and manufacturing solutions for the automotive, aeronautics, infrastructure, and other industrial sectors, integrating advanced technologies, such as robotics and artificial intelligence that, together with human interaction, contribute to a more sustainable development. It has an operational presence in thirteen countries in the main markets of Europe, America, and Asia; and contributes to the digital transformation and the automation and optimisation of its customers’ processes in the industrial field through sustainable and competitive growth.
Press contact:
Iñigo Palacio & Berta de Arístegui
(+34) 91 576 52 50
